© December 2025 | IJIRT | Volume 12 Issue 7 | ISSN: 2349-6002

Evolution of Nanotechnology in The Field of Sustainable Living and Healthcare

Dr. Chatti Nirmala Sai Manaswi[1], Dr.A.S.Shivasaravanan[2]
[1] *Research Scholar, Vinayaka Mission's Homoeopathic Medical College & Hospital, Salem;Assistant Professor, Department of Organon of Medicine and Homoeopathic Philosophy, JIMS Homoeopathic Medical College & Hospital, Hyderabad.*
[2] *Professor & Head, Department of Surgery, Vinayaka Mission's Homoeopathic Medical College & Hospital, Salem*

***Abstract*—Nanotechnology has emerged as a transformative scientific discipline with far reaching implications for sustainable living and modern healthcare. By enabling the manipulation of matter at the nanoscale (1–100 nm), this field has unlocked unique physicochemical properties that have revolutionized diagnostics, therapeutics, drug delivery, imaging, regenerative medicine, and biosensing. This chapter presents a comprehensive and chronological overview of the evolution of nanotechnology, tracing its conceptual origins from Richard Feynman's visionary ideas, through key technological breakthroughs such as scanning probe microscopy and engineered nanomaterials, to the establishment and expansion of nanomedicine as a distinct biomedical discipline. Major milestones including the development of liposomal and polymeric nanodrugs, targeted and stimuli responsive nanocarriers, quantum dots, theranostics, and gene delivery systems are critically discussed. The chapter further highlights the role of nanotechnology in sustainable healthcare, emphasizing precision medicine, reduced toxicity, improved therapeutic efficacy, and resource efficient interventions. Recent advances, such as lipid nanoparticle-based mRNA vaccines, AI integrated nanomedicine, nanorobotics, and regulatory evolution, underscore the maturity and global relevance of this field. The chapter concludes by outlining future directions, positioning nanotechnology as a cornerstone of sustainable, personalized, and integrative healthcare systems.**

***Index Terms*—Nanotechnology, Nanomedicine, Sustainable healthcare, Drug delivery systems, Targeted therapy**

I. INTRODUCTION

Nanotechnology has emerged as one of the most transformative scientific and technological revolutions of the 21st century. Defined as the design, manipulation, and application of materials and devices with at least one dimension in the range of 1–100 nanometres (nm), nanotechnology enables unprecedented control over matter at the molecular and atomic scale. At the nanoscale, materials exhibit unique physicochemical properties including altered reactivity, quantum effects, enhanced surface area to volume ratio, tunable optical characteristics, and improved mechanical behaviour that differ fundamentally from their bulk counterparts. These distinctive properties have opened new frontiers in physics, chemistry, engineering, and most notably, medicine.

The application of nanoscale science to health called nanomedicine, encompasses diagnostics, therapeutics, drug delivery, imaging, biosensing, regenerative medicine, and nano enabled medical devices. The convergence of material science, biotechnology, engineering, and molecular biology has pushed medical science into an era of precision, miniaturization, and targeted intervention. Nanotechnology promises to overcome longstanding limitations associated with conventional diagnostics and drug delivery, offering solutions such as improved bioavailability, controlled release, enhanced tissue penetration, reduced systemic toxicity, and increased therapeutic efficacy.

The evolution of nanotechnology in medicine is deeply rooted in a series of conceptual advances,

technological breakthroughs, and interdisciplinary collaborations. From Richard Feynman's prophetic 1959 lecture imagining molecular level engineering, to the development of scanning probe microscopes in the 1980s, to the first FDA approved nanodrug in 1995, and to the contemporary use of lipid nanoparticles in mRNA vaccine delivery, nanomedicine has progressed dramatically over six decades.
This chapter traces the historical progression and scientific evolution of nanotechnology in medicine, organized chronologically. It examines early conceptual foundations, emergence of enabling tools, the birth of nanomedicine as a discipline, technological expansions, regulatory developments, and the current and future landscape.

II. EARLY CONCEPTS (1950–1980)

2.1. Richard Feynman and the conceptual origin (1959)

Nanotechnology's philosophical beginning is widely attributed to physicist Richard Feynman's landmark lecture titled "There's Plenty of Room at the Bottom", delivered at the American Physical Society meeting at Caltech in 1959. Feynman proposed manipulating and controlling matter at the atomic level, envisioning miniaturized machines, molecule by molecule fabrication, and information storage in minuscule volumes. Although he did not use the term "nanotechnology," his ideas laid the intellectual foundation for the field.
Feynman articulated possibilities such as:
writing the entire Encyclopedia Britannica on the head of a pin,
constructing machines capable of building smaller machines,
performing surgery from within the human body using microscale tools,
and engineering matter atom by atom.
Although technologically impossible at the time, his predictions foreshadowed many aspects of modern nanomedicine, including nanoscale surgical tools, drug carrying nanobots, and molecular level diagnostic devices.

2.2. Norio Taniguchi and the first use of the term "nanotechnology" (1974)

Japanese scientist Norio Taniguchi introduced the term "nanotechnology" in 1974 while describing precision machining processes with tolerances below 100 nm. His work was primarily related to engineering, not biology or medicine, but it established a vocabulary for discussing nanoscale manipulation.

2.3. Emergence of molecular machines and nanorobotics concepts

The 1960s–1970s saw parallel developments that indirectly influenced nanomedicine:
Theoretical foundations for molecular machines by Drexler (late 1970s)
Advancements in molecular biology, including DNA structures, protein folding, and enzyme interactions
Polymer chemistry breakthroughs, enabling controlled synthesis of nanoscale polymers
These early foundations nurtured the idea that molecular scale constructs could be used to intervene in biological processes.

2.4. Beginnings of Nanoscale Material Science

By the early 1970s, the foundations of nanoscale material science began to take shape as researchers explored diverse classes of sub 100 nm structures for biomedical and analytical applications. Colloidal gold nanoparticles were increasingly utilised as contrast enhancers in electron microscopy, owing to their strong electron density and ease of surface function. Around the same period, liposomes, which was first described by Alec Bangham in 1965 were being investigated for drug encapsulation, membrane biophysics, and vesicular transport models, setting the stage for later therapeutic use. Parallel developments in polymer-based micelles and emulsion systems introduced additional amphiphilic nanocarriers capable of solubilising hydrophobic drug molecules. Although these early nanoparticulate platforms were mainly confined to fundamental biological and physicochemical studies, they ultimately provided the conceptual and technological foundations for modern nanodrug delivery systems.

III. TECHNOLOGICAL BREAKTHROUGHS (1980–2000)

The period between 1980 and 2000 marked a transformative era in nanotechnology, characterised by rapid expansion in experimental methodologies and nanoscale fabrication techniques. Major breakthroughs in scanning probe microscopy, advanced material synthesis, supramolecular chemistry, and surface engineering enabled scientists to visualise, manipulate, and construct structures at the atomic and molecular scale with unprecedented precision. Innovations such as the Scanning Tunnelling Microscope (1981) and Atomic Force Microscope (1986), combined with the discovery of engineered nanomaterials including fullerenes, carbon nanotubes, and quantum dots propelled nanotechnology from a conceptual domain into a rigorous, experimentally validated scientific discipline. These advancements not only accelerated fundamental nanoscale research but also catalysed the emergence of nanomedicine as a distinct translational field.

3.1. Scanning Tunneling Microscope (STM) 1981

Invented by Gerd Binnig and Heinrich Rohrer, the STM enabled the visualization of individual atoms on surfaces. This was the first experimental tool that allowed scientists to manipulate matter at the atomic level. It marked the beginning of practical nanoscale engineering and led to the birth of nanotechnology as a scientific discipline.

3.2. Atomic Force Microscope (AFM) 1986

The development of the Atomic Force Microscope (AFM) in 1986 by Binnig, Quate, and Gerber marked a major technological breakthrough that significantly advanced nanoscience and nanomedicine. Unlike electron microscopes, AFM enabled the imaging of non-conductive materials, including a wide range of biological structures, without requiring complex sample preparation. This ability to map biological surfaces at nanometre resolution opened entirely new possibilities in biomedical research. AFM allowed researchers to measure molecular forces, manipulate nanoscale particles, and characterise drug carriers and biomaterials with unparalleled precision. It soon became a foundational technology in nanomedicine, providing the first direct visual and mechanical insights into cells, biomolecules, and nanoscale therapeutic systems.

3.3. Advances in Engineered Nanomaterials

During the 1980s and 1990s, breakthroughs in engineered nanomaterials dramatically expanded the scope of nanotechnology for biomedical applications. The discovery of fullerenes (C60) in 1985 and carbon nanotubes (CNTs) in 1991 introduced unique carbon-based nanostructures with exceptional strength, electronic behaviour, and chemical versatility. Around the same time, the emergence of quantum dots (QDs) provided semiconductor nanoparticles with tunable optical properties that later transformed bioimaging. Colloidal gold and silver nanoparticles, which had been historically used in chemical and biological staining, were adapted into more refined formats suitable for diagnostics, photothermal applications, and drug delivery. Dendrimers, with their highly controlled and branched architecture, further enriched the nanomaterial toolbox by enabling precise surface functionalisation for targeted and controlled drug release. Collectively, these engineered nanomaterials contributed to major innovations in imaging, biosensing, photothermal therapy, tissue engineering, and targeted drug delivery systems.

3.4. Liposomes and the Birth of Nanodrug Delivery

Liposomes initially described by Alec Bangham in 1965 underwent substantial technological progress during the 1980s and 1990s, evolving from unstable lipid vesicles into clinically viable drug delivery platforms. Advances such as improved structural stability, PEGylation for longer circulation time, and controlled release formulations led to the development of sophisticated liposomal medicines. This culminated in the approval of Doxil® (liposomal doxorubicin) in 1995, the first FDA approved nanomedicine. Doxil's success marked the beginning of modern clinical nanomedicine by demonstrating how nanoscale formulations could reduce toxicity, enhance pharmacokinetics, and improve therapeutic outcomes.

3.5. Polymer Science and Nanocarriers

The 1990s also witnessed major progress in polymer science, with the introduction of polymeric nanoparticles, PLGA and PLA copolymers, PEGylated systems, polymeric micelles, emulsions, and stimuli responsive nanocarriers. These platforms provided enhanced control over drug release, stability, and biocompatibility. Their ability to be functionalised with targeting ligands or environmental triggers (such as pH or temperature) laid the foundation for next generation targeted drug delivery systems widely used today.

3.6. Conceptual Rise of Nanomedicine

The late 1990s saw the emergence of the term "nanomedicine," reflecting a growing recognition of the potential of nanoscale technologies in healthcare. At this stage, researchers began conceptualising nanoscale diagnostic tools, molecular imaging agents, cancer targeted therapies, nano enabled biosensors, and engineered tissue scaffolds. These conceptual developments provided the intellectual and technological foundation for the explosive growth of nanomedicine in the early 2000s.

IV. BIRTH OF NANOMEDICINE (1990–2005)

4.1. Nanotechnology Enters Biomedical Research

The 1990s were defined by increasing interdisciplinary collaboration among material scientists, biomedical engineers, pharmaceutical researchers, clinicians, and molecular biologists. This convergence gave rise to the field now known as nanomedicine. As researchers began adapting nanomaterials and nanoscale tools for biological systems, the early framework for nano-based diagnostics, therapeutics, and imaging began to take shape.

4.2. Liposomal and Polymeric Nanodrugs

The approval of Doxil in 1995 was followed by a series of nanoformulations that further legitimised the clinical value of nanotechnology. Liposomal amphotericin B (AmBisome), PEGylated liposomal drugs, and polymeric nanoparticle-based formulations expanded the therapeutic landscape across oncology, infectious diseases, and chronic conditions. These formulations demonstrated reduced systemic toxicity, enhanced pharmacokinetics, and improved tissue penetration compared with conventional therapeutics, marking a paradigm shift in drug delivery science.

4.3. Development of Targeted Drug Delivery

By the late 1990s and early 2000s, researchers moved beyond passive targeting mechanisms such as the enhanced permeability and retention (EPR) effect and began developing active targeting technologies. These included ligand conjugated nanoparticles, antibody drug conjugates, receptor specific nanocarriers, and pH responsive or stimuli responsive nanosystems. This transition represented a major scientific evolution, enabling nanoparticles to interact selectively with diseased cells while sparing healthy tissues.

4.4. Quantum Dots and Optical Imaging

Quantum dots emerged as powerful tools for biomedical imaging due to their exceptional brightness, tunable emission wavelengths, and superior resistance to photobleaching. Their ability to label and track cells with high precision revolutionised early cancer detection, cellular imaging, and molecular diagnostics, significantly advancing the field of optical nanomedicine.

4.5. Emergence of Theranostics

The early 2000s also saw the rise of theranostic nanomedicine, in which nanoparticles were designed to combine diagnostic imaging with therapeutic action. Gold nanoshells were engineered for simultaneous imaging and photothermal tumour ablation, while iron oxide nanoparticles served as dual purpose agents for MRI imaging and drug delivery. This integration of therapy and diagnostics remains one of the defining features of modern nanomedicine.

V. EXPANSION AND INNOVATIONS (2005–2020)

5.1. Explosive Growth of Nanomedicine Research

Between 2005 and 2020, nanomedicine experienced exponential growth in scientific publications, patents, clinical trials, and regulatory approvals. Nanotechnology became central to advancements in oncology, infectious diseases, neurology, cardiology, orthopaedics, and regenerative medicine. This period marked the global mainstreaming of nanomedicine as an essential pillar of biomedical innovation.

5.2. Gold Nanoparticles and Photothermal Therapy

Gold nanoparticles emerged as multifunctional platforms useful for photothermal tumour ablation, biosensing, imaging, and targeted gene delivery. Their tunable surface plasmon resonance allowed them to generate heat upon laser irradiation, enabling minimally invasive destruction of cancer cells.

5.3. Iron Oxide Nanoparticles and MRI Imaging

Superparamagnetic iron oxide nanoparticles (SPIONs) revolutionised MRI diagnostics by enhancing tumour detection, enabling stem cell tracking, and allowing targeted imaging of inflammatory disorders. Their biocompatibility and magnetic responsiveness made them one of the most clinically relevant nanomaterials of the era.

5.4. Carbon Nanomaterials
Further exploration of fullerenes, carbon nanotubes, and graphene derivatives expanded their role in biomedical engineering. These materials were used for drug loading, electrical stimulation of tissues, antimicrobial applications, antibiofilm therapies, and regenerative medicine, demonstrating the broad versatility of carbon nanostructures.

5.5. Rise of Nano enabled Regenerative Medicine
Nanotechnology greatly improved tissue engineering, introducing advanced scaffolds for bone regeneration, nanofibers for wound healing, nano hydroxyapatite for orthopaedic reconstruction, and nerve supportive scaffolds for neural tissue engineering. These innovations enhanced cell adhesion, proliferation, and differentiation, strengthening the field of regenerative medicine.

5.6. Nano enabled Biosensors and Diagnostics
Significant progress was made in nanoelectrode sensors, nanoplasmonic detection systems, paper based nanosensors, and wearable nano biosensing devices. These platforms enhanced sensitivity and specificity, enabling early detection of cancers, infectious diseases, genetic abnormalities, and metabolic disorders in both clinical and point of care settings.

5.7. Gene Delivery and RNA Nanotechnology
Nanocarriers became essential tools for delivering siRNA, plasmid DNA, CRISPR Cas components, and antisense oligonucleotides. These developments laid the foundation for the later emergence of mRNA-based therapeutics, culminating in global scale clinical application during the COVID 19 pandemic.

VI. MODERN NANOMEDICINE (2020–PRESENT)

6.1. Nanotechnology and COVID 19: A Global Validation
The most transformative milestone in modern nanomedicine was the successful deployment of lipid nanoparticles (LNPs) for mRNA delivery in the Pfizer BioNTech and Moderna COVID 19 vaccines. For the first time, nanoparticles were used on a global scale in billions of individuals, demonstrating the safety and effectiveness of nanocarrier based genetic vaccines. This achievement validated decades of research in nanotechnology and positioned nanomedicine as indispensable to modern healthcare and pandemic preparedness.

6.2. Advancements in Precision Nanomedicine
Recent years have seen the emergence of exosome mimicking nanoparticles, programmable nanocarriers, surface switching nanoparticles, and biomimetic nanosystems. These platforms are designed for highly precise therapeutic delivery, minimising off target effects and enabling personalised medicine approaches. Nano enabled immunotherapy is gaining prominence, offering improved strategies for cancer treatment and immune modulation.

6.3. Nanorobotics and Targeted Surgical Interventions
Cutting edge research is accelerating the development of micro and nanorobots capable of guided drug delivery, tissue penetration, and minimally invasive surgical interventions. Magnetically guided nanoswimmers and DNA origami based nanorobots represent pioneering systems with potential to revolutionise targeted therapies and precision intervention.

6.4. AI Integrated Nanomedicine
Artificial intelligence and machine learning are increasingly used to optimise nanocarrier design, predict nanoparticle behaviour and toxicity, and enhance the performance of theranostic platforms. The integration of AI accelerates discovery, reduces development time, and improves predictive accuracy in nanomedicine research.

6.5. Regulatory Evolution
Regulatory bodies such as the FDA, EMA, and Indian agencies have begun formalising frameworks to guide nanomedicine development. These include detailed standards for nanomaterial characterisation, pharmacokinetic and biodistribution modelling, safety evaluation, toxicology assessment, and clinical trial design. These efforts aim to improve safety, transparency, and therapeutic efficacy.

VII. FUTURE DIRECTIONS

Future advancements in nanomedicine are expected to focus on smart nanocarriers capable of dynamic responses to biological cues, personalised nanotherapeutics tailored to individual genetic profiles, and nano enabled immune engineering for precise modulation of immune responses. Other promising fields include artificial nanoenzymes (nanozymes), biohybrid nanorobots for highly targeted therapy, next generation nanovaccines, digitally integrated nano biosensors, organ specific nanotherapeutics, and quantum nanobiotechnology. These innovations promise to shape the next generation of precision medicine and integrative healthcare systems.

VIII. SUMMARY

The evolution of nanotechnology in medicine reflects a transition from theoretical concepts to clinically transformative technologies. Beginning with Feynman's atomic level vision, progressing through the invention of microscopes capable of imaging atoms, and expanding into targeted drug delivery, imaging, diagnostics, gene therapy, and vaccine technologies, nanomedicine now represents a foundational pillar of modern healthcare. Continued advancements promise to reshape therapeutic strategies, personalize medical interventions, and extend the boundaries of regenerative medicine, imaging, and molecular diagnostics.

MILESTONE TABLE: Evolution of Nanotechnology in Medicine

Year/Period	Milestone	Significance
1959	Feynman's "Plenty of Room at the Bottom"	Conceptual foundation of atomic level engineering
1974	Taniguchi coins "nanotechnology"	Provides terminology and framework
1981	Scanning Tunneling Microscope	Enables atomic imaging and manipulation
1985	Discovery of fullerenes (C60)	New carbon nanomaterial family
1986	Atomic Force Microscope	Imaging of biological samples at nanoscale
1991	Carbon nanotubes discovered	High strength, conductive nanostructures
1995	FDA approval of Doxil	First nanomedicine drug
2000–2005	Rise of targeted nanocarriers and theranostics	Combines therapy + imaging
2005–2015	Expansion in cancer nanotechnology & regenerative nanomedicine	Widespread research and clinical trials
2015–2019	Advances in gene delivery nano systems	RNA and DNA nanotechnology
2020	mRNA COVID 19 vaccines using lipid nanoparticles	Global validation of nanomedicine
2020–Present	AI integrated nanomedicine, nanorobotics, programmable nanoparticles	Future direction of medicine

REFERENCES

[1] Feynman RP. There's plenty of room at the bottom. Engineering and Science. 1960;23(5):22–36.

[2] Taniguchi N. On the basic concept of 'nanotechnology'. Proc Intl Conf Prod Eng. Tokyo: Japan Society of Precision Engineering; 1974.

[3] Drexler KE. Engines of Creation: The Coming Era of Nanotechnology. Anchor Press; 1986.

[4] Binnig G, Rohrer H. Scanning tunneling microscopy. Helv Phys Acta. 1982; 55:726–35.

[5] Binnig G, Quate CF, Gerber C. Atomic force microscope. Phys Rev Lett. 1986;56(9):930–3.

[6] Kroto HW, Heath JR, O'Brien SC, Curl RF, Smalley RE. C60: Buckminsterfullerene. Nature. 1985; 318:162–3.

[7] Iijima S. Helical microtubules of graphitic carbon. Nature. 1991; 354:56–8.

[8] Bangham A. Liposomes: the Babraham connection. Chem Phys Lipids. 1993; 64:275–85.

[9] Barenholz Y. Doxil® The first FDA approved nano drug. J Control Release. 2012; 160:117–34.

[10] Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev. 2013; 65:36–48.

[11] Alivisatos P. Semiconductor clusters, nanocrystals, and quantum dots. Science. 1996; 271:933–7.
[12] Chan WCW, Nie S. Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science. 1998; 281:2016–8.
[13] Parak WJ et al. biological applications of colloidal nanocrystals. Nanotechnology. 2005;16:R9–25.
[14] Torchilin VP. Multifunctional nanocarriers. Nat Rev Drug Discov. 2014; 13:813–27.
[15] Peer D et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007; 2:751–60.
[16] Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010; 7:653–64.
[17] Ferrari M. Cancer nanotechnology. Nat Rev Cancer. 2005; 5:161–71.
[18] Hao Y et al. Stimuli responsive nanoparticles for drug delivery. Adv Mater. 2018; 30:1705638.
[19] Giljohann DA et al. RNA interference nanotechnology. Angew Chem. 2010; 49:3280–94.
[20] Hou X et al. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021; 6:1078–94.
[21] Baden LR et al. Efficacy of the mRNA 1273 SARS CoV 2 Vaccine. N Engl J Med. 2021; 384:403–16.
[22] Polack FP et al. Safety and efficacy of the BNT162b2 mRNA vaccine. N Engl J Med. 2020; 383:2603–15.
[23] Liu Z et al. Carbon-based nanomaterials in medicine. Chem Rev. 2017; 117:11261–325.
[24] Rzigalinski BA, Strobl JS. Cadmium containing nanoparticles. Nanomedicine. 2009; 5:9–20.
[25] Duncan R, Gaspar R. Nanomedicine the translational gap. EJC. 2011; 47:1181–6.
[26] Etheridge ML et al. The big picture on nanomedicine. Nanomedicine. 2013; 9:1–14.
[27] Nel AE et al. Understanding biophysicochemical interactions at the nano–bio interface. Nat Mater. 2009; 8:543–57.
[28] Fadeel B, Garcia Bennett AE. Better safe than sorry: Understanding the toxicological profile of nanoparticles. Adv Drug Deliv Rev. 2010; 62:362–74.
[29] Jain KK. Applications of nanobiotechnology in clinical oncology. Cancer. 2008; 113:1576–84.
[30] Brayden DJ. Controlled release nanotechnology. Nat Biotechnol. 2013; 31:3912.31–65. Additional references included upon request.